Adenosinergic Signalling in Cervical Cancer Microenvironment

Despite the emergence of the first human papillomavirus vaccine, the incidence of cervical cancer is still responsible for more than 350,000 deaths yearly. Over the past decade, ecto-5′-nucleotidase (CD73/5′-NT) and extracellular adenosine (ADO) signalling has been the subject of many investigations...

Full description

Saved in:
Bibliographic Details
Published inExpert reviews in molecular medicine Vol. 27; p. e5
Main Authors Iser, Isabele Cristiana, Bertoni, Ana Paula Santin, Beckenkamp, Liziane Raquel, Consolaro, Marcia Edilaine Lopes, Maria-Engler, Silvya Stuchi, Wink, Marcia Rosângela
Format Journal Article
LanguageEnglish
Published Cambridge, UK Cambridge University Press 07.01.2025
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Despite the emergence of the first human papillomavirus vaccine, the incidence of cervical cancer is still responsible for more than 350,000 deaths yearly. Over the past decade, ecto-5′-nucleotidase (CD73/5′-NT) and extracellular adenosine (ADO) signalling has been the subject of many investigations to target cancer progression. In general, the adenosinergic axis has been linked to tumourigenic effects. However, CD73 can play contradictory effects, probably dependent on the tumour type, tumour microenvironment and tumour stage, thus being in some circumstances, inversely related to tumour progression. We herein reviewed the pathophysiological function of CD73 in cervical cancer and performed in silico analysis of the main components of the adenosinergic signalling in human tissues of cervical cancer compared to non-tumour cervix tissue. Our data showed that the NT5E gene, that encoded CD73, is hypermethylated, leading to a decreased CD73 expression in cervical cancer cells compared to normal cells. Consequently, the high availability of ADO cytoplasmatic/extracellular leads to its conversion to AMP by ADK, culminating in global hypermethylation. Therefore, epigenetic modulation may reveal a new role for CD73 in cervical cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Isabele Cristiana Iser and Ana Paula Santin Bertoni have contributed equally to this paper.
ISSN:1462-3994
1462-3994
DOI:10.1017/erm.2024.30